A monoclonal antibody specifically binding human progastrin (hPG) for use in a method of treating liver cancer or preventing recurrence of liver cancer, wherein said anti-hPG monoclonal antibody comprises V L and V H CDRs having sequences selected from one of the following groups of V L and V H CDR sequences: (i) V H CDR1.3 comprising the amino acid sequence of SEQ ID NO: 1, V H CDR 2.3 comprising the amino acid sequence of SEQ ID NO: 2, V H CDR 3.3 comprising the amino acid sequence of SEQ ID NO: 3, V L CDR 1.3 comprising the amino acid sequence of SEQ ID NO: 4, V L CDR 2.3 comprising the amino acid sequence of SEQ ID NO: 5, and V L CDR 3.3 comprising the amino acid sequence of SEQ ID NO: 6; (ii) V H CDR1.8 comprising the amino acid sequence of SEQ ID NO: 37, V H CDR 2.8 comprising the amino acid sequence of SEQ ID NO: 41, V H CDR 3.8 comprising the amino acid sequence of SEQ ID NO: 45, V L CDR 1.8 comprising the amino acid sequence of SEQ ID NO: 49, V L CDR 2.8 comprising the amino acid sequence of SEQ ID NO: 52, and V L CDR 3.8 comprising the amino acid sequence of SEQ ID NO: 55; (iii) V H CDR 1.13 comprising the amino acid sequence of SEQ ID NO: 38, V H CDR 2.13 comprising the amino acid sequence of SEQ ID NO: 42, V H CDR 3.13 comprising the amino acid sequence of SEQ ID NO: 46, V L CDR 1.13 comprising the amino acid sequence of SEQ ID NO: 50, V L CDR 2.13 comprising the amino acid sequence of SEQ ID NO: 53, and V L CDR 3.13 comprising the amino acid sequence of SEQ ID NO: 56. (iv) V H CDR 1.16 comprising the amino acid sequence of SEQ ID NO: 39, V H CDR 2.16 comprising the amino acid sequence of SEQ ID NO: 43, V H CDR 3.16 comprising the amino acid sequence of SEQ ID NO: 47, V L CDR 1.16 comprising the amino acid sequence of SEQ ID NO: 50, V L CDR 2.16 comprising the amino acid sequence of SEQ ID NO: 53, and V L CDR 3.16 comprising the amino acid sequence of SEQ ID NO: 57; (v) V H CDR 1.19 comprising the amino acid sequence of SEQ ID NO: 40, V H CDR 2.19 comprising the amino acid sequence of SEQ ID NO: 44, V H CDR 3.19 comprising the amino acid sequence of SEQ ID NO: 48, V L CDR 1.19 comprising the amino acid sequence of SEQ ID NO: 51, V L CDR 2.19 comprising the amino acid sequence of SEQ ID NO: 54, and V L CDR 3.19 comprising the amino acid sequence of SEQ ID NO: 58. (i) V H CDR1.3 comprising the amino acid sequence of SEQ ID NO: 1, V H CDR 2.3 comprising the amino acid sequence of SEQ ID NO: 2, V H CDR 3.3 comprising the amino acid sequence of SEQ ID NO: 3, V L CDR 1.3 comprising the amino acid sequence of SEQ ID NO: 4, V L CDR 2.3 comprising the amino acid sequence of SEQ ID NO: 5, and V L CDR 3.3 comprising the amino acid sequence of SEQ ID NO: 6; (ii) V H CDR1.8 comprising the amino acid sequence of SEQ ID NO: 37, V H CDR 2.8 comprising the amino acid sequence of SEQ ID NO: 41, V H CDR 3.8 comprising the amino acid sequence of SEQ ID NO: 45, V L CDR 1.8 comprising the amino acid sequence of SEQ ID NO: 49, V L CDR 2.8 comprising the amino acid sequence of SEQ ID NO: 52, and V L CDR 3.8 comprising the amino acid sequence of SEQ ID NO: 55; (iii) V H CDR 1.13 comprising the amino acid sequence of SEQ ID NO: 38, V H CDR 2.13 comprising the amino acid sequence of SEQ ID NO: 42, V H CDR 3.13 comprising the amino acid sequence of SEQ ID NO: 46, V L CDR 1.13 comprising the amino acid sequence of SEQ ID NO: 50, V L CDR 2.13 comprising the amino acid sequence of SEQ ID NO: 53, and V L CDR 3.13 comprising the amino acid sequence of SEQ ID NO: 56. (iv) V H CDR 1.16 comprising the amino acid sequence of SEQ ID NO: 39, V H CDR 2.16 comprising the amino acid sequence of SEQ ID NO: 43, V H CDR 3.16 comprising the amino acid sequence of SEQ ID NO: 47, V L CDR 1.16 comprising the amino acid sequence of SEQ ID NO: 50, V L CDR 2.16 comprising the amino acid sequence of SEQ ID NO: 53, and V L CDR 3.16 comprising the amino acid sequence of SEQ ID NO: 57; (v) V H CDR 1.19 comprising the amino acid sequence of SEQ ID NO: 40, V H CDR 2.19 comprising the amino acid sequence of SEQ ID NO: 44, V H CDR 3.19 comprising the amino acid sequence of SEQ ID NO: 48, V L CDR 1.19 comprising the amino acid sequence of SEQ ID NO: 51, V L CDR 2.19 comprising the amino acid sequence of SEQ ID NO: 54, and V L CDR 3.19 comprising the amino acid sequence of SEQ ID NO: 58.